Results 131 to 140 of about 276,376 (316)

Pre‐Existing and New‐Onset Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting.
Kimberley I. Hemelrijk   +23 more
wiley   +1 more source

Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Longer‐term morbidity post septal myectomy (SM) in obstructive hypertrophic cardiomyopathy has not been well characterized at a national level.
Ahmed Altibi   +6 more
doaj   +1 more source

Clinical and Echocardiographic Outcomes After Implantation of the ALLEGRA Transcatheter Valve Using the Fully Repositionable IMPERIA Delivery System: One‐Year Results of the EMPIRE I Study

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The EMPIRE I study assessed the early (30 days) safety and efficacy of a new fully repositionable delivery system (IMPERIA) for the commercially available ALLEGRA transcatheter aortic valve in patients with either severe native aortic stenosis or a degenerated surgical bioprosthesis.
José Antonio Baz   +15 more
wiley   +1 more source

Plasma CCL3 predicts adverse heart failure outcomes in patients with arrhythmogenic cardiomyopathy

open access: yesBMC Medicine
Background Fibro-fatty replacement of the myocardium plays a key role in the pathogenesis of arrhythmogenic cardiomyopathy (ACM) and may be associated with progressive heart failure (HF).
Hao Cui   +15 more
doaj   +1 more source

Nine‐Year Follow‐Up After M‐TEER for Secondary Mitral Regurgitation in a Patient With Cardiogenic Shock

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Transcatheter edge‐to‐edge repair (TEER) has become an established therapeutic option for patients with severe secondary mitral regurgitation (SMR). While randomized trials and registry data have reported outcomes up to 5 years, longer follow‐up data remain scarce.
Tobias Reithmayer   +9 more
wiley   +1 more source

Role of Neuroimaging Before Coronary Angiography in Patients With Out‐of‐Hospital Cardiac Arrest

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Patients presenting following out‐of‐hospital cardiac arrest (OOHCA) often require emergency coronary angiography. Presentations can be associated with syncope or head‐trauma. Aims We investigated the impact and utility of pre‐coronary angiography CT‐Brain (CT‐B) in patients following OOHCA on clinical outcomes.
Edmond Wong   +8 more
wiley   +1 more source

SCN5A Mutations Associate With Arrhythmic Dilated Cardiomyopathy and Commonly Localize to the Voltage-Sensing Mechanism.

open access: yes, 2011
OBJECTIVES: The aim of this study was to discern the role of the cardiac voltage-gated sodium ion channel SCN5A in the etiology of dilated cardiomyopathy (DCM).
SINAGRA, GIANFRANCO   +10 more
core   +1 more source

Cardiomyopathy

open access: yes
Cardiomyopathy includes a spectrum of conditions of various pathologies. The appropriate diagnostic tools should be used to achieve the diagnosis and plan the appropriate management.
Maged William (21133769)
core  

Cardiomyopathies: Current Treatment and Future Options

open access: yes
The reprint highlights different forms of cardiomyopathy, such as RBM20, filamin C, and lamin A/C cardiomyopathy. Diagnostic and new treatment options are presented in arrhythmogenic, hypertrophic, dilated, and restrictive cardiomyopathy.

core   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy